Get the Stockscreener App
7.90
8.82%
0.64
After Hours:
7.72
-0.18
-2.28%
Replimune Group Inc stock is traded at $7.90, with a volume of 1.20M.
It is up +8.82% in the last 24 hours and down -20.44% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$7.26
Open:
$7.2
24h Volume:
1.20M
Relative Volume:
0.32
Market Cap:
$619.70M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-2.50
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+8.22%
1M Performance:
-20.44%
6M Performance:
+181.64%
1Y Performance:
-39.32%
1-Day Range:
$7.20
$7.91
1-Week Range:
$6.77
$7.91
52-Week Range:
$2.68
$14.80
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
7.90 | 569.50M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune Group (NASDAQ:REPL) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Aug Analyst Calls: Is now the right time to enter Replimune Group IncQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Replimune Group (NASDAQ:REPL) Trading Down 5.4%Should You Sell? - MarketBeat
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference - TipRanks
Replimune Group, Inc. Updates on RP1 and RP2 Programs - TradingView — Track All Markets
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-11 11:23:41 - Улправда
Why Replimune Group Inc. stock remains a top recommendationNew Releases Roundup & HOKA model picks for your routine - ulpravda.ru
Why Replimune Group Inc. stock is seen as undervaluedCPI Data & Consistent Return Investment Signals - Улправда
How institutional buying supports Replimune Group Inc. stock - ulpravda.ru
Replimune Group (NASDAQ:REPL) Shares Up 10.9%Should You Buy? - MarketBeat
Will Replimune Group Inc. stock reach all time highs in 20252026 world cup usa national team qualification star players possession football winner prediction expert opinion - ulpravda.ru
Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL) - MarketBeat
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - 富途牛牛
HC Wainwright & Co. Upgrades Replimune Group (REPL) - MSN
Replimune Group (NASDAQ:REPL) Shares Down 6.4%What's Next? - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - MSN
Replimune announces priority review for its melanoma treatment - MSN
Replimune Group (NASDAQ:REPL) Trading Up 4.8%Should You Buy? - MarketBeat
Replimune Group Inc (HAM:7R8) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Replimune Group Inc. stock overvalued by current metricsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
How Replimune Group Inc. stock trades during market volatility2025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Why Replimune Group Inc. stock could benefit from AI revolution2025 Fundamental Recap & Weekly Return Optimization Alerts - Улправда
Is Replimune Group Inc. stock supported by strong fundamentalsJuly 2025 Setups & Smart Swing Trading Alerts - Улправда
Why hedge funds are buying Replimune Group Inc. stock2025 Dividend Review & Free Reliable Trade Execution Plans - DonanımHaber
Aug Catalysts: Why Replimune Group Inc. stock remains a top recommendation - Улправда
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - TMX Newsfile
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech pioneering oncolytic immunotherapies to speak at J.P. Morgan - Stock Titan
Replimune Shares Face Mounting Headwinds - AD HOC NEWS
Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness - simplywall.st
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Replimune Group earns relative strength rating upgrade; hits key benchmark - MSN
What analysts say about Replimune Group Inc stockVolume Spike Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Replimune Group, Inc. $REPL Holdings Trimmed by Braidwell LP - MarketBeat
Replimune Group (NASDAQ:REPL) Director Kapil Dhingra Sells 3,169 Shares - MarketBeat
Replimune Group, Inc. $REPL Shares Sold by Redmile Group LLC - MarketBeat
Replimune Group Director Kapil Dhingra Sells All Shares - TradingView — Track All Markets
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Replimune Group, Inc. $REPL Shares Sold by Marshall Wace LLP - MarketBeat
Nan Fung Group Holdings Ltd Lowers Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune Stock Presents a Complex Investment Narrative - AD HOC NEWS
Saturn V Capital Management LP Takes $1.20 Million Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group CEO Sushil Patel Sells 10,000 Shares - TradingView
CEO Patel Sells 10,000 ($111.3K) Of Replimune Group Inc [REPL] - TradingView
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):